• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

FDA starts review of Argenx drug in rare disease CIDP

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 20, 2024 at 11:12: AM
via The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the company tries to turn around a run of bad news with the drug.

article source
 

<



Similar threads

cafead
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
Replies
0
Views
95
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts review of Padcev/Keytruda for bladder cancer
Replies
0
Views
102
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts speedy review of Servier&#039;s Tibsovo in MDS
Replies
0
Views
223
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA starts review of Sanofi, AZ antibody for RSV prevention
Replies
0
Views
315
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lilly takes long view on Alzheimer’s drug hopeful as FDA starts expedited review
Replies
0
Views
247
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote